CDC warns of an association betw severe CNS arboviral disease, w/ neurologic sequelae in pts receiving anti-CD20 mAbs (rituximab, ocrelizumab, ofatumumab, obinutuzumab, etc). West Nile virus was the most common arbovirus, but there are others; mortality up to 40%. Most arbovirus https://t.co/7eMoNgWbB4

Systemic Burden of Gout https://t.co/OUgXMtH1bn https://t.co/zK7vRCevTY

JAMA has updated its guidance for the acceptable use of AI in authoring a Medical Publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. This is about what is permitted & not permitted & what needs to be disclosed. https://t.co/zti0OnvBV0 https://t.co/6VHiEPGxUf

Study of 154 anti-Ku Ab+ pts (51 IMMM, 46 SLE, 30 Sjögrens, 27 Sc) = 60 (39%) had ILD - 75% progressed; more rapidly in males. BUT Ku+ is rare <4%, not specific, without clear clinical implications. Ku is a myositis-assoc Ab (like Ro52/Ro60, U1-RNP, PM/Scl) https://t.co/s1VFhaOYgn

New, Advanced Therapies in Gout https://t.co/7i6936H7ZS https://t.co/8oOzqVKLGF

2026 BSR Pain Guideline: What Rheumatologists Need to Know The British Society for Rheumatology has issued its first guideline dedicated solely to pain in inflammatory arthritis (IA)—covering RA, PsA, axial SpA and JIA. https://t.co/3Jtneox8Rh https://t.co/06ccLhjhMh

Updated Guidance for Artificial Intelligence Use in Medical Publications JAMA has updated its guidance for the acceptable use of artificial intelligence (AI) in authoring a medical publication. Despite growing AI use, very low rates of disclosure of AI use have been reported. https://t.co/irid5koIjo

NHANES survey (2005-2018) studied prevalence of arthritis in adults w/ depression (PHQ-9 ≥10), From 15157 depressed pts, RA was most prevalent & increased 7.8 to 17.7%; OA unchanged 11.7 to 10.7% & PsA declined 7.2 to 1.7%. Depression assoc w/ higher risk for RA (OR 1.40) & PsA https://t.co/fcROEvsHDT

2026 PGY1 match for non–US citizen international medical graduates (IMGs) has reached a 5-year low; yet US health care relies heavily on non–US-born MDs. In US, there are 6300 Rheumatologists - 46.9% US born USMG; 5.4% US born IMG; 11.2% non-US born USMG; 36.5% non-US born IMG https://t.co/cwx5ugBaVE

Biomarker substudy from SENSCIS trial of nintedanib in SSc-ILD shows higher baseline KL-6 levels >1000 U/mL was assoc w/ greater FVC worsening; & decrease in CA-125 was assoc. w/ nintedanib responses. Epithelial cells are primary source of CA-125 in the lung https://t.co/7VJ2UDOKin

Evaluating Inflammatory Joint Pain in Older Adults Lee, Levinson, and Makris have published an approach to evaluating inflammatory joint pain in older adults in JAMA Internal Medicine. While intended to be a practical guide for Primary Care Clinicians (PCCs), the tenets and https://t.co/TPKEOjkcKl

Wealth and Where you Live Influences Outcomes Patients from wealthier European countries tend to start treatment with biologics earlier but also stop or switch treatment earlier. They also experience lower disease activity at treatment start than patients in middle- and https://t.co/MyzWRx580R

Survey: Upgrading & Maximizing the Classics (Urate Lowering Therapies, etc) https://t.co/w6uzIlaeG7 https://t.co/HW09DVrMed

What's New in Lyme Disease JAMA has published an overview of new considerations on Lyme disease, focusing on Diagnostics, Vaccines, and Prevention. https://t.co/jG09wc6gI8 https://t.co/rQBW6RIz5U

"Be so good they can't ignore you." - Steve Martin https://t.co/lMRAY57rW9